Skip to content
value.today

Evozyne, LLC

🇺🇸 Chicago, Illinois, USABiotechnologyFounded 2019
Total raised
$144 M
3 rounds on record
Latest round
$81 M
Sep 2023
First round on record
Apr 2020
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Evozyne, LLC
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2023$81 MNo. 3$50 to $250 million

Evozyne, LLC: Raise no. 3, Sep 2023

Investors in this round

29 investors had bought by the notice of Sep 29, 2023: 29 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$81 M of $100 M offered; $19 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,046,080
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Aleina M. Lee · Executive Officer · Corporate Controller
  • Aris J. Theologis · Executive Officer · Chief Business Officer
  • Arjun S. Rallapalli · Executive Officer · Chief Operating Officer
  • Darien S. Parhad · Executive Officer · Chief Financial Officer and Treasurer
  • Jeffrey S. Aronin · Executive Officer, Director · Chairman and Director
  • Jude M. Sullivan · Executive Officer · General Counsel and Secretary
  • Mike S. Gamson · Executive Officer, Director · President, Chief Executive Officer, and Director
  • Patrick J. Morris · Executive Officer, Director · Executive Vice President, Legal Affairs, Assistant Secretary, and Director
  • Rama J. Ranganathan · Executive Officer, Director · Chief Scientific Officer and Director
  • Antonio S. Gracias · Director · Director
  • Matthew M. Rizzo · Director · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Paragon Health Capital, LLC (CRD 300729) · Chicago, IllinoisSold in CA, FL, IL, MA, NY

Remarks in the notice

  • On the amounts: “Total sold includes sale of secured conv promissory notes amounting to $40500061 in aggregate. Total Remaining includes approx $9,499,940 of remaining equity to be sold & approx $9499940 of remaining secured convertible promissory notes to be sold.”

Signed by Jude Sullivan, General Counsel and Secretary. Source: SEC Form D, newest notice filed Sep 29, 2023. Read the notice at the SEC.

equity, debtSEC
Apr 2021$54 MNo. 2$50 to $250 million

Evozyne, LLC: Raise no. 2, Apr 2021

Investors in this round

12 investors had bought by the notice of Apr 22, 2021: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$54 M of $59 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,613,675
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Aris J. Theologis · Executive Officer, Director
  • Darien S. Parhad · Executive Officer
  • Patrick J. Morris · Executive Officer, Director
  • Rama J. Ranganathan · Executive Officer, Director
  • Antonio S. Gracias · Director
  • Jeffrey S. Aronin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Paragon Health Capital (CRD 300729) · Chicago, IllinoisSold in IL, MA

Signed by Patrick J. Morris, President. Source: SEC Form D, newest notice filed Apr 22, 2021. Read the notice at the SEC.

equitySEC
Apr 2020$9 MNo. 1$2 to $10 million

Evozyne, LLC: Raise no. 1, Apr 2020

Investors in this round

2 investors had bought by the notice of May 7, 2020: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $9 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Aris J Theologis · Executive Officer, Director · Manager and Chief Business Officer
  • Darien J Parhad · Executive Officer · Treasurer
  • Jeffrey S. Aronin · Executive Officer, Director · Chairman of the Board of Managers
  • Patrick J Morris · Executive Officer, Director · Manager, Interim Chief Executive Officer, Interim President, Executive Vice President, Legal Affairs and General Counsel
  • Rama J Ranganathan · Executive Officer, Director · Manager and Chief Scientific Officer
  • Antonio J Gracias · Director · Manager

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Offering is closed.”

Signed by Patrick J. Morris, EVP, Legal Affairs and General Counsel. Source: SEC Form D, newest notice filed May 7, 2020. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Evozyne, LLC chose not to state its revenue in its newest notice of a funding round (Sep 2023).

    SEC Form D · Sep 2023

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2023

That is all the official record says: Evozyne, LLC has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Evozyne, LLC is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 29 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Evozyne, LLC
NameRoleNamed in
Aleina M. LeeCorporate ControllerSep 2023
Aris J. TheologisChief Business OfficerSep 2023
Arjun S. RallapalliChief Operating OfficerSep 2023
Darien S. ParhadChief Financial Officer and TreasurerSep 2023
Jeffrey S. AroninChairman and DirectorSep 2023
Jude M. SullivanGeneral Counsel and SecretarySep 2023
Mike S. GamsonPresident, Chief Executive Officer, and DirectorSep 2023
Patrick J. MorrisExecutive Vice President, Legal Affairs, Assistant Secretary, and DirectorSep 2023
Rama J. RanganathanChief Scientific Officer and DirectorSep 2023
Aris J TheologisManager and Chief Business OfficerMay 2020
Darien J ParhadTreasurerMay 2020
Patrick J MorrisManager, Interim Chief Executive Officer, Interim President, Executive Vice President, Legal Affairs and General CounselMay 2020
Rama J RanganathanManager and Chief Scientific OfficerMay 2020
Antonio S. GraciasDirectorSep 2023
Jeffrey S. AroninChairman and DirectorSep 2023
Matthew M. RizzoDirectorSep 2023
Mike S. GamsonPresident, Chief Executive Officer, and DirectorSep 2023
Patrick J. MorrisExecutive Vice President, Legal Affairs, Assistant Secretary, and DirectorSep 2023
Rama J. RanganathanChief Scientific Officer and DirectorSep 2023
Aris J. TheologisDirectorApr 2021
Antonio J GraciasManagerMay 2020
Aris J TheologisManager and Chief Business OfficerMay 2020
Patrick J MorrisManager, Interim Chief Executive Officer, Interim President, Executive Vice President, Legal Affairs and General CounselMay 2020
Rama J RanganathanManager and Chief Scientific OfficerMay 2020